Targeting the mTOR pathway using deforolimus in cancer therapy

Author： Mahalingam Devalingam   Sankhala Kamalesh   Mita Alain   Giles Francis J   Mita Monica M  

Publisher： Future Medicine

ISSN： 1479-6694

Source： Future Oncology, Vol.5, Iss.3, 2009-04, pp. : 291-303

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Metformin sensitizes chemotherapy by targeting cancer stem cells and the mTOR pathway in esophageal cancer

By                

International Journal of Oncology, Vol. 45, Iss. 2, 2014-01 ,pp. : 567-574

Spandidos Publications

Access to resources Recommend Favorite

Mechanisms of mTOR inhibitor resistance in cancer therapy

By Carew Jennifer  

Targeted Oncology, Vol. 6, Iss. 1, 2011-03 ,pp. : 17-27

Springer Publishing Company

Access to resources Recommend Favorite

Targeting mTOR in cancer: renal cell is just a beginning

By Azim Hamdy  

Targeted Oncology, Vol. 5, Iss. 4, 2010-12 ,pp. : 269-280

Springer Publishing Company

Access to resources Recommend Favorite

Targeting mTOR: Evaluating the Therapeutic Potential of Resveratrol for Cancer Treatment

By  

Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry - Anti-Cancer Agents), Vol. 13, Iss. 7, 2013-09 ,pp. : 1032-1038

Bentham Science Publishers

Access to resources Recommend Favorite

NRSF/REST regulates the mTOR signaling pathway in oral cancer cells

By  

Oncology Reports, Vol. 33, Iss. 3, 2015-01 ,pp. : 1459-1464

Spandidos Publications

Access to resources Recommend Favorite